Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Interested in new trials?
Get alerts for new trials in your area by subscribing now
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
What are scleroderma clinical trials?
Scleroderma clinical trials study ways to slow the excess collagen buildup at the root of the disease, protect organs like the lungs and kidneys from damage, and manage complications like Raynaud's phenomenon and digital ulcers. Because scleroderma affects people so differently, from skin-only disease to serious organ involvement, trials often target a specific subtype or complication rather than the disease broadly.
Why are clinical trials important for scleroderma research?
Scleroderma still has no cure, and it took until 2019 for the first FDA-approved therapy to target its most dangerous complication, lung scarring. Progress has been unusually slow partly because the disease looks so different from person to person, which makes it hard to study as a single condition. Trials that recruit narrowly, by subtype or by which organs are affected, are how that pace is finally starting to pick up.
What types of scleroderma clinical trials are there?
Scleroderma trials generally target either the skin and underlying immune process directly, lung involvement specifically since that drives the most serious complications, or vascular problems like Raynaud's and digital ulcers. A smaller number test more intensive approaches, including stem cell transplants, for people with severe early diffuse disease who haven't responded to standard options.
Who can participate in scleroderma clinical trials?
Eligibility depends on which type and how much organ involvement you have, since a trial for early diffuse skin disease looks very different from one focused on lung or kidney complications. Many studies require recent diagnosis, specific antibody test results, or documented lung function decline to qualify. Eligibility always varies by study.
Are scleroderma clinical trials paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
Is it safe to participate in scleroderma clinical trials?
Every study is reviewed by an independent ethics board before enrollment opens, and monitoring is typically frequent given how many organs scleroderma can affect. The specific risks of any study are walked through during informed consent, before you agree to anything.
Worried about the risks of participating in a clinical trial? Delve into our comprehensive guide to gain insights into the potential outcomes of participating. Learn about potential risks, benefits, and safety considerations to make an informed decision about your participation in a clinical trial.